新論文研究:定期使用伊維菌素預防 COVID-19 以劑量反應方式導致 COVID-19 死亡率降低 92%:對 88,012 名受試者的嚴格控制人群的前瞻性觀察研究結果

八月底的的一項巴西新研究發現,伊維菌素是一種通用的抗寄生蟲藥,在阻止武漢冠狀病毒 (Covid-19) 引起的死亡方面的有效率為 92%。

Flavio A. Cadegiani 博士在推特上介紹了這項研究,他說,當用作預防劑時,伊維菌素具有“劑量反應效應”,這意味著“你使用得越多,你得到的保護就越多。

每隔 15 天定期服用伊維菌素至少 6 到 8 週的人幾乎都在“新冠肺炎”中倖存下來,而那些沒有服用伊維菌素的人在疾病結束後死亡的可能性要大得多。

研究結果與耶魯醫學院受人尊敬的流行病學家 Harvey Risch 博士的研究結果一致,他在參議院作證說,伊維菌素和羥氯喹 (HCQ) 可以挽救數千甚至數百萬因不使用這些藥物而不必要地失去的生命.

與此同時,美國食品和藥物管理局 (FDA) 一直在對伊維菌素發起攻勢,稱其為“驅蟲劑”,儘管早在 1990 年代就批准了這種藥物供人類使用。

大型科技公司也在盡其所能,審查有關伊維菌素的帖子,稱其為“錯誤信息”。當權者真的不希望人們使用伊維菌素,因為他們知道伊維菌素有效,而且如果伊維菌素廣泛可用,沒有人會服用“疫苗”。


論文連結:
https://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-population-of-88012-subjects?email_share=true&expedited_modal=true

Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects

Background We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 (COVID-19), irrespective of the regularity, in a strictly controlled citywide progr...

https://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-population-of-88012-subjects?email_share=true&expedited_modal=true
Past 31 days
Total Visit: 0
There are 0 fact-checking replies to the message
No response has been written yet. It is recommended to maintain a healthy skepticism towards it.
Add Cofacts as friend in LINE
Add Cofacts as friend in LINE
LINE 機器人
查謠言詐騙